tirzepatide cvs pharmacy CVS Health chooses Wegovy over Lilly's Zepbound

CVS brings back coverage for Lilly's obesity drug Zepbound

27.79

★★★★☆4.8 (126)

CVS Dropping Zepbound: What It Means For Patients, Payers, And Pharma

29.94

★★★★★4.9 (98)

CVS Dropped Zepbound: What It Means and How You Can Still Get Tirzepatide

27.37

★★★★★5.0 (157)

CVS Health will remove #Zepbound from its preferred formulary starting July 1, 2025, favoring #Wegovy instead. This decision impacts patient access to weight-loss medications, despite Zepbound showing superior results in the SURMOUNT-5

22.64

★★★★★4.7 (84)

A major shift is unfolding in the obesity treatment landscape as CVS Health announced expanded coverage for Zepbound while also adding @Eli Lilly and Company 's new direct to consumer platform, Foundayo,

26.77

★★★★★4.9 (203)

CVS Health announced it will remove Zepbound (tirzepatide) from its preferred formulary list starting July 1, 2025, opting instead to prioritize Wegovy (semaglutide). This formulary change reflects broader negotiations between pharmaceutical companies

25.91

★★★★★5.0 (176)

CVS Caremark drops Zepbound coverage for Wegovy for weight loss – WFTV

22.64

★★★★★4.8 (132)